These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11716889)

  • 21. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure.
    Klotz S; Danser AH; Foronjy RF; Oz MC; Wang J; Mancini D; D'Armiento J; Burkhoff D
    J Am Coll Cardiol; 2007 Mar; 49(11):1166-74. PubMed ID: 17367660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T; Takeshita A
    Nihon Rinsho; 2003 May; 61(5):801-6. PubMed ID: 12755006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
    Remme WJ
    Cardiol Clin; 2007 Nov; 25(4):581-94; vii. PubMed ID: 18063162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
    G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life?
    Fowler MB
    Eur Heart J; 1998 Dec; 19 Suppl P():P17-25. PubMed ID: 9886708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: what we know and current controversies.
    Moser DK; Biddle MJ
    Crit Care Nurs Clin North Am; 2003 Dec; 15(4):423-37, vii-viii. PubMed ID: 14717387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H; Moukarbel GV; Dawson B; Hajjar RJ; Francis GS
    Am J Med; 2007 Dec; 120(12):1090.e1-8. PubMed ID: 18060931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term improvement in submaximal exercise capacity by optimized therapy with ACE inhibitors and beta blockers in heart failure patients is associated with restoration of peripheral endothelial function.
    Poelzl G; Frick M; Lackner B; Huegel H; Alber HF; Mair J; Herold M; Schwarzacher SP; Pachinger O; Weidinger F
    Int J Cardiol; 2006 Mar; 108(1):48-54. PubMed ID: 16516697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?
    van de Wal RM; van Veldhuisen DJ; van Gilst WH; Voors AA
    Eur Heart J; 2005 Nov; 26(22):2361-7. PubMed ID: 16105846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
    Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
    Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III.
    Willenheimer R; Erdmann E; Follath F; Krum H; Ponikowski P; Silke B; Van Veldhuisen DJ; Van De Ven L; Verkenne P; Lechat P;
    Eur J Heart Fail; 2004 Jun; 6(4):493-500. PubMed ID: 15182776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
    McMurray JJ; Pitt B; Latini R; Maggioni AP; Solomon SD; Keefe DL; Ford J; Verma A; Lewsey J;
    Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
    McMurray JJ; Ostergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA;
    Lancet; 2003 Sep; 362(9386):767-71. PubMed ID: 13678869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure.
    Gage JR; Fonarow G; Hamilton M; Widawski M; Martínez-Maza O; Vredevoe DL
    Neuroimmunomodulation; 2004; 11(3):173-80. PubMed ID: 15067208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alpha-1 adrenoceptor-angiotensin II type 1 receptor cross-talk and its relevance in clinical medicine.
    Vittorio TJ; Fudim M; Wagman G; Kosmas CE
    Cardiol Rev; 2014; 22(2):51-5. PubMed ID: 23707993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.
    Pietrasik G; Goldenberg I; McNitt S; Polonsky B; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2009 Apr; 20(4):395-400. PubMed ID: 19017351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.